Redenlab supporting Larimar Therapeutics in Phase 1 SAD Clinical Trial

Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

Click here to learn more.

Tags: ,

Related Post

Redenlab partners with BDCRC to support new NIH-funded Batten disease research

  • Posted on 19 November, 2025
    MEDIA RELEASE MELBOURNE, VIC - A newly formed research network focused on Batten disease, a rare and inherited brain disorder...
    Read more

    Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia

    • Posted on 25 July, 2025
      A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with ataxia-telangiectasia (A-T),...
      Read more

      What can speech tell us about pain?

      • Posted on 26 June, 2025
        Pain is deeply personal, yet universally expressed through speech. But what if speech isn’t just a way we describe pain,...
        Read more